PF-Atlas › Clinical Trials › NCT05389215
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
DWN12088 · Phase 2
Registry ID
NCT05389215
Phase
Phase 2
Status
Active, not recruiting
Drug / intervention
DWN12088
Sponsor
Daewoong Pharmaceutical Co. LTD.
Start
2022-07-29
Enrollment
102
Locations
30
About this trial
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT05389215 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.